• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Ocular Therapeutix Inc. (Amendment)

    2/14/24 7:48:57 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OCUL alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. _____5___)*

     

    Ocular Therapeutix, Inc.

     

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    67576A100

     

    (CUSIP Number)

     

    James Silverman, One Boston Place, 26th Floor, Boston, MA 02108

     

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    12/31/2023

     

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
    CUSIP No. 67576A10013GPage 2 of 4 Pages

     

    1. NAMES OF REPORTING PERSONS Opaleye Management Inc.
       
     

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) 20-5648796

       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
       
      (a) ☐
      (b) ☐
    3. SEC USE ONLY
       
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Massachusetts

    NUMBER OF SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON WITH

    5. SOLE VOTING POWER
       
      0
    6. SHARED VOTING POWER
       
      6,070,000
    7. SOLE DISPOSITIVE POWER
       
      0
    8. SHARED DISPOSITIVE POWER
       
      6,070,000

    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      6,070,000
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)
       
      ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      5.51%
    12. TYPE OF REPORTING PERSON (see instructions)
       
      CO

     

     
    CUSIP No. 67576A10013GPage 3 of 4 Pages

     

    Item 1.

     

      (a) Name of Issuer Ocular Therapeutix, Inc. (the “Company”)
         
      (b) Address of Issuer’s Principal Executive Offices 24 Cosby Drive, Bedford, MA 01730

     

    Item 2.

     

    (a) 

    Name of Person Filing Opaleye, L.P.

     
    (b) 

    Address of the Principal Office or, if none, residence One Boston Place, 26th Floor, Boston, MA 02108

       
    (c)

    Citizenship USA

         
    (d) 

    Title of Class of Securities Common Stock, par value $0.0001 per share

         
    (e) 

    CUSIP Number 67576A100

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned: 6,070,000
         
      (b) Percent of class: 5.51%
         
      (c) Number of shares as to which the person has: 6,070,000

     

        (i) Sole power to vote or to direct the vote 0
           
        (ii) Shared power to vote or to direct the vote 6,070,000
           
        (iii) Sole power to dispose or to direct the disposition of 0
           
        (iv) Shared power to dispose or to direct the disposition of 6,070,000

     

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Instruction. Dissolution of a group requires a response to this item.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Item 9. Notice of Dissolution of Group.

     

    Item 10. Certification.

     

      (a)   The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):
           
          By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
           
      (b)   The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):
           
          By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 67576A10013GPage 4 of 4 Pages

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      02/14/2024
      Date
       
      /s/ James Silverman
     

    Signature

     

      James Silverman, President

      Name/Title

     

     

    Get the next $OCUL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OCUL

    DatePrice TargetRatingAnalyst
    4/8/2025Outperform
    William Blair
    3/18/2025$17.00Outperform
    RBC Capital Mkts
    3/11/2025$15.00Buy
    Needham
    10/16/2024Sector Outperform
    Scotiabank
    6/20/2024$7.00 → $11.00Hold → Buy
    TD Cowen
    5/31/2024$15.00Overweight
    Piper Sandler
    2/9/2024$15.00Buy
    BofA Securities
    4/21/2023$18.00Outperform
    Robert W. Baird
    More analyst ratings

    $OCUL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for Registrational Trial of AXPAXLI™ in NPDR

    BEDFORD, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced it has received written agreement regarding a registrational trial design from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the Company's planned clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of non-proliferative diabetic retinopathy (NPDR). "Securing a Special Protocol Assessment agreement from the FDA for our planned NPDR trial represents a major milestone as we look to broaden the impact of AXPAXLI beyond wet AMD and in

    8/12/25 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and Business Highlights

    Outstanding patient retention and clinical execution in complementary AXPAXLI™ SOL trials for wet AMD SOL-1 remains on track for 1Q 2026 topline data SOL-R rescue criteria streamlined and simplified with topline data expected in 1H 2027 Planning to incorporate single long-term extension study for both SOL trials Ocular to host Investor Day on Tuesday, September 30, 2025, in New York City Raised gross proceeds of approximately $97 million in June 2025 through existing ATM facility Cash balance of $391.1 million as of June 30, 2025, with expected runway into 2028, well beyond anticipated topline data for SOL-1 and SOL-R BEDFORD, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Ocular Thera

    8/5/25 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025

    BEDFORD, Mass., July 29, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, August 5, 2025 at 8:00 AM ET to discuss recent business progress and financial results for the second quarter ended June 30, 2025. Conference Call and Webcast Information: Date: Tuesday, August 5, 2025, at 8:00 AM ET Participant Dial-In (U.S.): 1-877-407-9039 Participant Dial-In (International): 1-201-689-8470 Webcast Access: Please click here The live and archived webcast can also be accessed by visiting the Ocular Therapeutix webs

    7/29/25 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCUL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Ocular Therapeutix

    William Blair initiated coverage of Ocular Therapeutix with a rating of Outperform

    4/8/25 9:29:59 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on Ocular Therapeutix with a new price target

    RBC Capital Mkts initiated coverage of Ocular Therapeutix with a rating of Outperform and set a new price target of $17.00

    3/18/25 7:53:57 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham initiated coverage on Ocular Therapeutix with a new price target

    Needham initiated coverage of Ocular Therapeutix with a rating of Buy and set a new price target of $15.00

    3/11/25 7:42:03 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCUL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lindstrom Richard L Md bought $69,600 worth of shares (10,000 units at $6.96), increasing direct ownership by 6% to 172,704 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    5/12/25 8:50:46 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summer Road Llc bought $7,000,000 worth of shares (930,851 units at $7.52) (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/27/24 4:43:51 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summer Road Llc bought $4,999,998 worth of shares (1,538,461 units at $3.25) (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    12/18/23 4:52:33 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCUL
    SEC Filings

    View All

    SEC Form 10-Q filed by Ocular Therapeutix Inc.

    10-Q - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

    8/5/25 7:11:07 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

    8/5/25 7:06:36 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Ocular Therapeutix Inc.

    SCHEDULE 13G - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

    7/8/25 9:07:31 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCUL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Waheed Nadia was granted 40,363 shares, increasing direct ownership by 20% to 247,168 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    8/14/25 5:51:43 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Dugel Pravin gifted 250,361 shares and received a gift of 250,361 shares, decreasing direct ownership by 7% to 3,248,738 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    8/13/25 7:02:24 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Meyers Steve Lawrence claimed ownership of 152,728 shares (SEC Form 3)

    3 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    6/23/25 9:12:26 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCUL
    Leadership Updates

    Live Leadership Updates

    View All

    Ocular Therapeutix® to Host Investor Day on June 13, 2024

    Company to highlight corporate strategy, clinical data, and development plans for AXPAXLI™ in wet AMD and NPDR Event to feature prominent retinal disease experts Baruch D. Kuppermann, MD, PhD (University of California, Irvine) and Dilsher S. Dhoot, MD (California Retina Consultants) In-person event with virtual access to take place on June 13, 2024, at 2:00 PM ET BEDFORD, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD

    6/5/24 7:30:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ Reports First Quarter 2024 Results

    Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3 wet AMD Trial Progressing with First Subjects Randomized in April 2024 Cash Expected to Support Operations Into 2028, Based on $482.9M March 31, 2024, Cash Balance June 13, 2024, Investor Day to Outline Updated Corporate Strategy BEDFORD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degenerati

    5/7/24 4:05:00 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

    Nadia K. Waheed, MD, MPH, Appointed Chief Medical Officer; Peter K. Kaiser, MD, to Become Chief Development Officer; Andrea Gibson, PhD, Named Vice President, Medical Collaborations; and Namrata Saroj, OD, to Become Development Strategy Consultant Dr. Waheed's strong industry track record as a CMO and broad expertise in wet AMD and diabetic retinopathy support advancing the Phase 3 AXPAXLI™ program Dr. Kaiser's vast leadership experience in numerous pivotal trials of approved wet AMD products enhances Ocular's transition to a leading retina care company Dr. Gibson and Dr. Saroj bring deep experience in clinical trial execution through their joint involvement in the development and commerc

    4/16/24 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCUL
    Financials

    Live finance-specific insights

    View All

    Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and Business Highlights

    Outstanding patient retention and clinical execution in complementary AXPAXLI™ SOL trials for wet AMD SOL-1 remains on track for 1Q 2026 topline data SOL-R rescue criteria streamlined and simplified with topline data expected in 1H 2027 Planning to incorporate single long-term extension study for both SOL trials Ocular to host Investor Day on Tuesday, September 30, 2025, in New York City Raised gross proceeds of approximately $97 million in June 2025 through existing ATM facility Cash balance of $391.1 million as of June 30, 2025, with expected runway into 2028, well beyond anticipated topline data for SOL-1 and SOL-R BEDFORD, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Ocular Thera

    8/5/25 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025

    BEDFORD, Mass., July 29, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, August 5, 2025 at 8:00 AM ET to discuss recent business progress and financial results for the second quarter ended June 30, 2025. Conference Call and Webcast Information: Date: Tuesday, August 5, 2025, at 8:00 AM ET Participant Dial-In (U.S.): 1-877-407-9039 Participant Dial-In (International): 1-201-689-8470 Webcast Access: Please click here The live and archived webcast can also be accessed by visiting the Ocular Therapeutix webs

    7/29/25 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025

    BEDFORD, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to issue a press release regarding first quarter 2025 financial results on Monday, May 5, 2025 at 7:00 AM Eastern Time. The Company will not be hosting a first quarter 2025 conference call and plans to resume quarterly earnings calls for its second quarter 2025 financial results. Information about the Company's quarterly results, conference calls, webcasts and other investor information are posted on the Company's website. About Ocular Therapeutix, Inc.Ocular Therapeutix, Inc.

    4/28/25 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCUL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

    SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

    11/14/24 5:49:38 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Ocular Therapeutix Inc.

    SC 13G - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

    11/14/24 9:37:26 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

    SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

    11/12/24 4:49:23 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care